With a market capitalization (market cap) of $1.38B — a measure of how much the company is worth — LB Pharmaceuticals Inc Common Stock is the 2352nd most valuable company in Healthcare as of August 10, 2026. Shares trade at $48.00, down +0.37% on the day.
of 2,573
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Visit websiteAs of August 10, 2026, LB Pharmaceuticals Inc Common Stock (LBRX) is worth $1.38B — this is its market capitalization, the total value of all its outstanding shares.
LB Pharmaceuticals Inc Common Stock’s market cap is $1.38B, which ranks it #2352 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
LB Pharmaceuticals Inc Common Stock (LBRX) shares trade at $48.00, down 0.37% on the day, as of August 10, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025